Amgen Inc. Stock

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-22 pm EDT 5-day change 1st Jan Change
271.9 USD +1.11% Intraday chart for Amgen Inc. +2.41% -5.59%
Sales 2024 * 32.97B Sales 2025 * 34.15B Capitalization 144B
Net income 2024 * 6.1B Net income 2025 * 7.56B EV / Sales 2024 * 5.79 x
Net Debt 2024 * 46.47B Net Debt 2025 * 40.28B EV / Sales 2025 * 5.4 x
P/E ratio 2024 *
23.5 x
P/E ratio 2025 *
18.1 x
Employees 26,700
Yield 2024 *
3.45%
Yield 2025 *
3.73%
Free-Float 99.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.11%
1 week+2.41%
Current month-4.36%
1 month-1.54%
3 months-12.33%
6 months-0.42%
Current year-5.59%
More quotes
1 week
260.68
Extreme 260.68
273.14
1 month
260.68
Extreme 260.68
288.57
Current year
260.68
Extreme 260.68
329.72
1 year
211.71
Extreme 211.71
329.72
3 years
198.64
Extreme 198.64
329.72
5 years
166.30
Extreme 166.3
329.72
10 years
108.20
Extreme 108.2
329.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 06-05-31
Director of Finance/CFO 65 19-10-22
Chief Tech/Sci/R&D Officer 52 Dec. 17
Members of the board TitleAgeSince
Director/Board Member 67 17-02-02
Director/Board Member 68 16-10-13
Director/Board Member 75 14-10-16
More insiders
Date Price Change Volume
24-04-22 271.9 +1.11% 2,139,135
24-04-19 268.9 +2.35% 3,380,330
24-04-18 262.8 -0.50% 2,082,791
24-04-17 264.1 -0.59% 2,175,120
24-04-16 265.6 +0.05% 2,017,573

Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT

More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
268.9 USD
Average target price
300.3 USD
Spread / Average Target
+11.65%
Consensus